Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy
More than 100 drugs have been approved to treat cancer, but predicting which ones will help a particular patient is an inexact science at best.
A new device developed at MIT may change that. The implantable device, about the size of the grain of rice, can carry small doses of up to 30 different drugs. After implanting it in a tumor and letting the drugs diffuse into the tissue, researchers can measure how effectively each one kills the patient’s cancer cells.
Such a device could eliminate much of the guesswork now involved in choosing cancer treatments, says Oliver Jonas, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and lead author of a paper describing the device in the April 22 online edition of Science Translational Medicine.
“You can use it to test a patient for a range of available drugs, and pick the one that works best,” Jonas says.
The paper’s senior authors are Robert Langer, the David H. Koch Professor at MIT and a member of the Koch Institute, the Institute for Medical Engineering and Science, and the Department of Chemical Engineering; and Michael Cima, the David H. Koch Professor of Engineering at MIT and a member of the Koch Institute and the Department of Materials Science and Engineering.
Putting the lab in the patient
Most of the commonly used cancer drugs work by damaging DNA or otherwise interfering with cell function. Recently, scientists have also developed more targeted drugs designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
In some cases, doctors extract tumor cells, grow them in a lab dish, and treat them with different drugs to see which ones are most effective. However, this process removes the cells from their natural environment, which can play an important role in how a tumor responds to drug treatment, Jonas says.
“The approach that we thought would be good to try is to essentially put the lab into the patient,” he says. “It’s safe and you can do all of your sensitivity testing in the native microenvironment.”
The device, made from a stiff, crystalline polymer, can be implanted in a patient’s tumor using a biopsy needle. After implantation, drugs seep 200 to 300 microns into the tumor, but do not overlap with each other. Any type of drug can go into the reservoir, and the researchers can formulate the drugs so that the doses that reach the cancer cells are similar to what they would receive if the drug were given by typical delivery methods such as intravenous injection.
After one day of drug exposure, the implant is removed, along with a small sample of the tumor tissue surrounding it, and the researchers analyze the drug effects by slicing up the tissue sample and staining it with antibodies that can detect markers of cell death or proliferation.
Ranking cancer drugs
To test the device, the researchers implanted it in mice that had been grafted with human prostate, breast, and melanoma tumors. These tumors are known to have varying sensitivity to different cancer drugs, and the MIT team’s results corresponded to those previously seen differences.
The researchers then tested the device with a type of breast cancer known as triple negative, which lacks the three most common breast cancer markers: estrogen receptor, progesterone receptor, and Her2. This form of cancer is particularly aggressive, and none of the drugs used against it are targeted to a specific genetic marker.
Using the device, the researchers found that triple negative tumors responded differently to five of the drugs commonly used to treat them. The most effective was paclitaxel, followed by doxorubicin, cisplatin, gemcitabine, and lapatinib. They found the same results when delivering these drugs by intravenous injection, suggesting that the device is an accurate predictor of drug sensitivity.
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- From Poop To Personalized Medicineon March 23, 2020 at 11:38 pm
With sufficient data, personalized microbiome-based therapies may become mainstream, and even the recommendations of probiotics use may need an update, Lim said. “I think that the biggest myth is the ...
- Personalized Medicine Market to Register Significant Gains Over 2019 to 2026on March 19, 2020 at 11:14 pm
Personalized Medicine Market (by product:Therapeutics) (by product:Diagnostics) (by product:Personalized Nutrition & Wellness) (by product:Personalized Medical Care) – Global Industry Analysis, Market ...
- Global Population Health Management Markets, 2020-2025 - Emerging Opportunities in Personalized and Value-Based Medicineon March 19, 2020 at 5:39 pm
Dublin, March 19, 2020 -- The "Population Health Management Market by Component (Software, Services), Mode of Delivery (On-premise Mode of Delivery, Cloud-based Mode of.
- Personalized Medicine Market Competitive Outlookon March 19, 2020 at 5:23 am
The Personalized Medicine Market Research Report is a useful research manual that provides basic data on each part of the business that is required for the development of teleological choice and ...
- New Personalized Medicine Findings from Washington University Describedon March 17, 2020 at 4:01 pm
2020 MAR 17-- By a News Reporter-Staff News Editor at Insurance Daily News-- Investigators discuss new findings in Drugs and Therapies- Personalized Medicine. According to news originating from St.
- Key Advances in Sarcoma Lead to More Personalized Medicine Effortson March 17, 2020 at 6:39 am
Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more ...
- Personalized Medicine Market 2020 Global Market Size, Analysis, Share, Research, Business Growth and Forecast to 2026 Research Reports Worldon March 16, 2020 at 12:24 am
Global "Personalized Medicine Market" 2020 Industry Research Report is a professional and in-depth study on the current state of the Global Personalized Medicine industry. Moreover, research report ...
- Hua Medicine Announces 2019 Annual Resultson March 15, 2020 at 10:19 pm
Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 WeeksDorzagliatin-Driven Portfolio Expands SHANGHAI, China, March 16, 2020 ...
- Global Personalized Medicine Study, 2018-2028: Focus on Scientific & Commercial Aspects and Profiles of 338 Companies Involvedon March 12, 2020 at 6:13 pm
The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes the latest concepts of ...
- The Future Of Healthcare: Data-Driven Personalized Medicine At Scaleon March 11, 2020 at 5:31 am
Huge challenges remain, but unlocking data will generate insights and knowledge that improve the efficiency and effectiveness of the healthcare system.
via Bing News